Keyphrases
Carbapenem-resistant Acinetobacter Baumannii
100%
Acinetobacter Infections
100%
Cefiderocol
100%
Antibiotics
37%
Baumannii
25%
Cefiderocol Resistance
25%
Treatment Options
12%
Monotherapy
12%
Synergism
12%
Hydrolysis
12%
Clinical Efficacy
12%
In Vitro Activity
12%
Moderate to Severe
12%
Clinical Practice Guidelines
12%
Current Treatment
12%
Clinical Setting
12%
Preclinical Data
12%
Pseudomonas Aeruginosa (P. aeruginosa)
12%
β-lactamase
12%
Randomized Clinical Trial
12%
Combination Therapy
12%
Carbapenem Resistance
12%
Antibiotic Treatment
12%
Health Problems
12%
World Health Organization
12%
Gram-negative Pathogens
12%
Current Role
12%
Pharmacokinetics-pharmacodynamics (PK-PD)
12%
Therapy Development
12%
Non-inferiority
12%
New Antibiotics
12%
Surveillance Data
12%
Susceptibility Rate
12%
Sulbactam
12%
Carbapenem-resistant Gram-negative
12%
Non-fermented
12%
Metallo-β-lactamase
12%
Siderophore Cephalosporin
12%
Avibactam
12%
Medicine and Dentistry
Carbapenem
100%
Cefiderocol
100%
Acinetobacter Infection
100%
In Vitro
30%
Antibiotics
30%
Pathogen
20%
Penicillinase
20%
Acinetobacter Baumannii
20%
Infection
10%
Monotherapy
10%
Prospective Study
10%
Combination Therapy
10%
Antibiotic Therapy
10%
Pseudomonas aeruginosa
10%
Randomized Clinical Trial
10%
Pharmacodynamics
10%
Pharmacokinetics
10%
Siderophore
10%
Serine
10%
Therapy Development
10%
Cephalosporin
10%
Sulbactam
10%
Avibactam
10%
Enzymatic Hydrolysis
10%
Diseases
10%
Pharmacology, Toxicology and Pharmaceutical Science
Carbapenem
100%
Cefiderocol
100%
Acinetobacter Infection
100%
Antibiotics
30%
Infectious Agent
20%
Penicillinase
20%
Acinetobacter Baumannii
20%
Infection
10%
Combination Therapy
10%
Monotherapy
10%
Synergism
10%
Prospective Study
10%
Pharmacodynamics
10%
Pseudomonas aeruginosa
10%
Randomized Clinical Trial
10%
Serine
10%
Carbapenem Resistance
10%
Siderophore
10%
Cephalosporin
10%
Sulbactam
10%
Avibactam
10%
Pharmacokinetics
10%
Diseases
10%